Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $298

Benzinga Newsdesk www.benzinga.com Positive 75.2%

Neg 0% Neu 0% Pos 75.2%

Piper Sandler analyst David Amsellem maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $294 to $298.